A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Pfizer
Pfizer
Canadian Cancer Trials Group
Valerio Therapeutics
National Institutes of Health Clinical Center (CC)
Galectin Therapeutics Inc.